| # | Country | Total Patents | |
|---|---|---|---|
| #1 | WIPO (World Intellectual Property Organization) | 5 | |
| #2 | United States | 4 | |
| #3 | Australia | 3 | |
| #4 | Canada | 3 | |
| #5 | China | 3 | |
| #6 | EPO (European Patent Office) | 3 | |
| #7 | Republic of Korea | 3 | |
| #8 | Mexico | 3 | |
| #9 | Hong Kong | 2 | |
| #10 | Israel | 2 | |
| #11 | Taiwan | 2 | |
| #12 | Singapore | 1 |
| # | Industry | |
|---|---|---|
| #1 | Pharmaceuticals | |
| #2 | Organic fine chemistry | |
| #3 | Biotechnology | |
| #4 | Medical technology | |
| #5 | Computer technology | |
| #6 | Chemical engineering |
| # | Name | Total Patents |
|---|---|---|
| #1 | Kung Hank F | 27 |
| #2 | Choi Seok Rye | 27 |
| #3 | Ploessl Karl | 26 |
| #4 | Zha Zhihao | 26 |
| #5 | Wu Zehui | 25 |
| #6 | Liu Futao | 8 |
| #7 | Seok Rye Choi | 3 |
| #8 | Zehui Wu | 3 |
| #9 | Hank F Kung | 3 |
| #10 | Karl Ploessl | 3 |
| Publication | Filing date | Title |
|---|---|---|
| WO2020220023A1 | Prostate-specific membrane antigen (psma) inhibitors as diagnostic and radionuclide therapeutic agents | |
| TW201906818A | Novel erbium-substituted positron emission tomography (PET) developer and its pharmacological application | |
| WO2018160544A1 | Radiopharmaceutical labeling device | |
| US2017189568A1 | Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy | |
| WO2017007790A1 | Hbed-bisphosphonates, radiometal conjugates thereof and their use as theranostic agents |